AVEO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVEO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AVEO Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $11.50 Mil. AVEO Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $27.19 Mil. AVEO Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $28.85 Mil. AVEO Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2022 was 1.34.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for AVEO Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of AVEO Pharmaceuticals was 11.85. The lowest was -7.28. And the median was 0.30.
The historical data trend for AVEO Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVEO Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | -0.45 | -0.70 | 1.06 | 0.41 | 0.83 |
AVEO Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.65 | 0.83 | 1.03 | 1.26 | 1.34 |
For the Biotechnology subindustry, AVEO Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where AVEO Pharmaceuticals's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
AVEO Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.011 | + | 37.96) | / | 45.87 | |
= | 0.83 |
AVEO Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (11.495 | + | 27.185) | / | 28.845 | |
= | 1.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVEO Pharmaceuticals (NAS:AVEO) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Jebediah Ledell | officer: Chief Operating Officer | C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Michael P Bailey | director, officer: President & CEO | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Michael Ferraresso | officer: Chief Commercial Officer | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Kevin Joseph Cullen | director | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Epperly Corinne | director | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Forest Baskett | 10 percent owner | |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Scott D Sandell | 10 percent owner | |
Growth Equity Opportunities Iv, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Erick Lucera | officer: Chief Financial Officer | 138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
Scarlett Spring | director | AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By PRNewswire PRNewswire • 10-25-2022
By PRNewswire PRNewswire • 10-18-2022
By Stock market mentor Stock market mentor • 01-06-2023
By PRNewswire PRNewswire • 10-31-2022
By PRNewswire PRNewswire • 11-10-2022
By Business Wire Business Wire • 10-19-2022
By Stock market mentor Stock market mentor • 01-03-2023
By deactivated_deactivated_Ds*** deactivated_deactivated_Ds*** • 10-12-2022
By PurpleRose PurpleRose • 07-11-2022
By PurpleRose PurpleRose • 07-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.